December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
July 2025 in “Frontiers in Medicine” Topical immunotherapy can help with severe hair loss, but results vary and need personalized, long-term treatment.
COVID-19 may trigger or worsen rapid hair loss in alopecia areata.
1 citations
,
December 2023 in “Experimental Dermatology” Children with alopecia areata before age 4 may have better short-term hair regrowth.
1 citations
,
February 2025 in “Journal of the American Academy of Dermatology” Most men prefer keeping their eyebrows over scalp hair.
10 citations
,
August 2022 in “JAAD Case Reports” Oral tofacitinib effectively regrows hair in children with alopecia areata without major side effects.
August 2025 in “Australasian Journal of Dermatology” Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.
18 citations
,
November 2022 in “The Journal of Dermatology” Alopecia areata affects 1.45% of people in Japan, impacting mood and self-esteem, with many not seeking treatment.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
6 citations
,
April 2024 in “Health Science Reports” Younger patients with severe alopecia areata often have nail problems.
5 citations
,
September 2023 in “Clinical Cosmetic and Investigational Dermatology” Patients with Alopecia Areata often have higher anxiety and depression.
3 citations
,
February 2025 in “Journal of Dermatological Treatment” Hair regrowth in Alopecia Areata patients leads to increased satisfaction and reduced stress.
2 citations
,
October 2025 in “Frontiers in Medicine” Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
2 citations
,
September 2024 in “International Journal of Dermatology” Children with alopecia areata and their caregivers experience significant emotional and quality of life challenges.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
2 citations
,
June 2023 in “Skin Research and Technology” Yellow dots and short vellus hairs are the most common signs of Alopecia Areata (AA), and trichoscopy can help diagnose AA and track treatment progress.
2 citations
,
September 2021 Patients with alopecia areata may have lower vitamin D levels than healthy people.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
1 citations
,
December 2022 in “Journal of cosmetic dermatology” The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.
1 citations
,
May 2025 in “Australasian Journal of Dermatology” Caregivers of teens with alopecia areata face significant mental and work-related challenges.
May 2026 in “Journal of Neurosciences in Rural Practice” Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.
May 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” Impaired autophagy may contribute to alopecia areata.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
November 2025 in “British Journal of Dermatology” The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.
August 2025 in “JEADV Clinical Practice” Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
June 2025 in “American Journal of Dermatopathology” Granulomatous Alopecia Areata is rare and may be caused by hair antigens or follicle destruction.
Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.